[Elsevier] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded

Fatma25 Post time 8 min. ago | Show all posts |Read mode
This post will be closed automatically in 2026-08-28 21:41
Reward10points


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    30


Return to the list